Response Genetics' Q2 Revenues Drop 23 Percent as ResponseDX Sales Climb | GenomeWeb

NEW YORK (GenomeWeb) – Response Genetics today reported that its second quarter revenues declined 23 percent year over year, but were up 10 percent on a sequential basis.

The Los Angeles-based molecular diagnostics firm brought in total revenues of $4.3 million for the three months ended June 30, down from $5.3 million for the second quarter of 2013. The company said that the decline was due to pharmaceutical client revenue, which varies quarter to quarter. In addition, last year's Q2 included a $500,000 milestone payment from GlaxoSmithKline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.